Nurix Therapeutics Inc. (NRIX)
18.56
-0.45 (-2.37%)
At close: Jan 14, 2025, 3:59 PM
18.65
0.48%
After-hours Jan 14, 2025, 05:20 PM EST
undefined% (undefined)
| Bid | 15.5 |
| Market Cap | 1.31B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.9 |
| PE Ratio (ttm) | -6.4 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 28.5 |
| Volume | 1,039,355 |
| Avg. Volume (20D) | 910,662 |
| Open | 19.29 |
| Previous Close | 19.01 |
| Day's Range | 18.39 - 19.80 |
| 52-Week Range | 7.65 - 29.56 |
| Beta | undefined |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 284
Stock Exchange NASDAQ
Ticker Symbol NRIX
Website https://www.nurixtx.com
Analyst Forecast
According to 17 analyst ratings, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 75.11% from the latest price.
Buy 94.12%
Hold 5.88%
Sell 0.00%
1 month ago ·
Source
+6.78%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
1 month ago ·
Source
+6.53%
Nurix Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $35.
